TARTAN-HF:糖尿病高危患者靶向筛查未诊断心力衰竭
TARTAN-HF 是一项前瞻性、多中心、非盲随机对照试验,纳入西苏格兰地区 706 例 40 岁及以上、无已知心衰的 1 型或 2 型糖尿病合并至少 1 项心衰危险因素患者。干预组行 NT-proBNP 筛查,若≥125 pg/mL 则行超声心动图,对照组接受常规诊疗。6 个月时筛查组心衰诊断率显著高于对照组(24.6% vs 1%),提示基于利钠肽的筛查策略可识别大量未被发现的症状性心衰。
要点
- 对糖尿病合并心衰危险因素者,NT-proBNP≥125 pg/mL 触发超声心动图的心衰筛查策略诊断率显著高于常规诊疗。
- 糖尿病高危患者中未被识别的心衰以射血分数保留型为主(23%)。
- 筛查发现心衰后,SGLT2 抑制剂使用率从 24% 升至 39%。
核心结论
- 基于 NT-proBNP 的心衰筛查策略在糖尿病合并心衰危险因素患者中可识别出大量未被发现的症状性心衰,且以射血分数保留型心衰为主。
研究设计与样本
- TARTAN-HF 为前瞻性、多中心、非盲随机对照试验,对象为西苏格兰地区 40 岁以上、无已知心衰的 1 型或 2 型糖尿病合并至少 1 项心衰危险因素患者。
- 从 2023 年 1 月 11 日至 2025 年 5 月 29 日共随机 706 例,筛查组 354 例,常规诊疗组 352 例。
- 中位年龄 71 岁,男性占 69%,2 型糖尿病占 90%,糖尿病中位病程 12.5 年,26% 有 2 项心衰危险因素,10% 有 3 项及以上。
主要发现
- 6 个月时心衰诊断率筛查组 87 例(24.6%),常规诊疗组 2 例(1%),OR 58(95% CI 14-236,P<0.001)。
- 筛查发现的心衰多数为射血分数保留型(23%)。
- 需筛查人数(NNS)为 5(95% CI 4-6)。
- 筛查组 SGLT2 抑制剂使用率从 24% 升至 39%。
- 筛查发现未识别心衰的患者 KCCQ-12 总评分中位 65.6,显著低于无心衰者的 89.6。
关键数值与推荐
- 纳入标准为年龄≥40 岁、1 型或 2 型糖尿病、至少 1 项心衰危险因素、无已知心衰。
- 干预方案为 NT-proBNP≥125 pg/mL 时行超声心动图检查。
- 心衰定义依据 2021 年欧洲心脏病学会心衰指南。
临床怎么用
- 对糖尿病合并心衰危险因素的患者,可考虑采用 NT-proBNP 检测进行心衰筛查。
- NT-proBNP≥125 pg/mL 时应行超声心动图进一步评估心衰及其表型。
- 筛查发现心衰后应及时启动改善预后的药物,包括 SGLT2 抑制剂。
局限性
- 研究为非盲设计,干预组接受超声心动图可能影响心衰诊断的判定。
- 研究人群来自西苏格兰地区,结果外推至其他人群时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with diabetes. OBJECTIVES: The purpose of this trial was to evaluate the diagnostic yield of a natriuretic peptide-based HF screening strategy in people with diabetes and HF risk factors. METHODS: TARTAN-HF (Targeted Assessment in high-Risk paTients with diAbetes to ideNtify undiagnosed HF) was a prospective, multicenter, unblinded, randomized controlled trial. Community-based participants aged ≥40 years with type 1 or type 2 diabetes and at least 1 additional HF risk factor, but without known HF, were recruited in the west of Scotland. Participants were randomized to N-terminal pro-B-type natriuretic peptide screening (with echocardiography if N-terminal pro-B-type natriuretic peptide ≥125 pg/mL) or usual care. The primary outcome was a HF diagnosis at 6 months. HF was defined according to 2021 European Society of Cardiology Heart Failure guidelines. Secondary and exploratory outcomes included HF phenotype, sodium-glucose cotransporter 2 inhibitor use, and a composite of HF hospitalization or death. RESULTS: From January 11, 2023 to May 29, 2025, 706 participants were randomized (354 screening; 352 usual care). Median age was 71 years, 69% were male, and 90% had type 2 diabetes. Median duration of diabetes was 12.5 years. Two HF risk factors were present in 26% and 3 or more risk factors in 10%. At 6 months, HF was diagnosed in 87 (24.6%) in the screening group vs 2 (1%) in usual care (OR: 58; 95% CI: 14-236; P < 0.001). Most cases were HF with preserved ejection fraction (23%). The number needed to screen was 5 (95% CI: 4-6). Sodium-glucose cotransporter 2 inhibitor use increased from 24% to 39% in the screening group. Patients found to have unrecognized HF had significantly impaired health status as assessed using the Kansas City Cardiomyopathy Questionnaire-12 overall summary score compared with those without HF (median: 65.6 vs 89.6). CONCLUSIONS: A HF screening strategy identified a large proportion of patients living with diabetes with unrecognized symptomatic HF (mostly HF with preserved ejection fraction). Screening strategies for HF should be further investigated and considered for adoption in the care of people with diabetes. (Targeted Assessment in high-Risk paTients with diAbetes to ideNtify undiagnosed Heart Failure: NCT05705869).
引用
- Taylor-Sweet, Petrie, McKinley, et al. Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). J Am Coll Cardiol. 2026. PMID: 42615958. doi:10.1016/j.jacc.2026.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。